{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T02:05:42Z","timestamp":1777946742437,"version":"3.51.4"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2019A1515110119"],"award-info":[{"award-number":["2019A1515110119"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017610","name":"Shenzhen Science and Technology Innovation Program","doi-asserted-by":"publisher","award":["RCBS20221008093104016"],"award-info":[{"award-number":["RCBS20221008093104016"]}],"id":[{"id":"10.13039\/501100017610","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006606","name":"Natural Science Foundation of Tianjin Municipality","doi-asserted-by":"publisher","award":["20JCZDJC00780"],"award-info":[{"award-number":["20JCZDJC00780"]}],"id":[{"id":"10.13039\/501100006606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81172162"],"award-info":[{"award-number":["81172162"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673012"],"award-info":[{"award-number":["81673012"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82402147"],"award-info":[{"award-number":["82402147"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.cellimm.2026.105100","type":"journal-article","created":{"date-parts":[[2026,3,29]],"date-time":"2026-03-29T23:23:16Z","timestamp":1774826596000},"page":"105100","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Armed oncolytic adenovirus elicits a \u201cself-feeder\u201d effect to supercharge NK cells for solid tumor control"],"prefix":"10.1016","volume":"423-424","author":[{"given":"Qibin","family":"Liao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siqiang","family":"Lai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongyi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingshu","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanzheng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junchang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohua","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.cellimm.2026.105100_bb0005","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.cellimm.2026.105100_bb0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.01242","article-title":"PD\/1-PD-ls checkpoint: insight on the potential role of NK cells","volume":"10","author":"Pesce","year":"2019","journal-title":"Front. Immunol"},{"key":"10.1016\/j.cellimm.2026.105100_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2026.101269","article-title":"CAR-T\/NK\/M-based combination therapies in cancer: a comprehensive review","volume":"61","author":"Vaja","year":"2026","journal-title":"Curr. Probl. Cancer"},{"issue":"2","key":"10.1016\/j.cellimm.2026.105100_bb0020","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","article-title":"Roles of natural killer cells in immunity to cancer, and applications to immunotherapy","volume":"23","author":"Wolf","year":"2023","journal-title":"Nat. Rev. Immunol"},{"issue":"1","key":"10.1016\/j.cellimm.2026.105100_bb0025","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-022-01672-z","article-title":"NK cells and solid tumors: therapeutic potential and persisting obstacles","volume":"21","author":"Tong","year":"2022","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.cellimm.2026.105100_bb0030","doi-asserted-by":"crossref","DOI":"10.1111\/jcmm.18362","article-title":"Natural killer cell-related anti-tumour adoptive cell immunotherapy","volume":"28","author":"Qi","year":"2024","journal-title":"J. Cell. Mol. Med"},{"issue":"1","key":"10.1016\/j.cellimm.2026.105100_bb0035","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1681869","article-title":"TCB2, a new anti-human interleukin-2 antibody, facilitates heterodimeric IL-2 receptor signaling and improves anti-tumor immunity","volume":"9","author":"Lee","year":"2019","journal-title":"Oncoimmunology"},{"issue":"7","key":"10.1016\/j.cellimm.2026.105100_bb0040","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071577","article-title":"Cytokine-induced memory-like NK cells with high reactivity against acute leukemia blasts and solid tumor cells suitable for adoptive immunotherapy approaches","volume":"13","author":"Tanzi","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.cellimm.2026.105100_bb0045","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0030264","article-title":"Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells","volume":"7","author":"Denman","year":"2012","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.cellimm.2026.105100_bb0050","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.4049\/jimmunol.1000328","article-title":"IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-\u03b3 production","volume":"186","author":"Jaime-Ramirez","year":"2011","journal-title":"J. Immunol"},{"issue":"5","key":"10.1016\/j.cellimm.2026.105100_bb0055","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00262-011-1122-3","article-title":"Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12","volume":"61","author":"Dowell","year":"2012","journal-title":"Cancer. Immunol. Immunother"},{"issue":"3","key":"10.1016\/j.cellimm.2026.105100_bb0060","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/CJI.0b013e318209e7ec","article-title":"Costimulation through the CD137\/4-1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function","volume":"34","author":"Hernandez-Chacon","year":"2011","journal-title":"J. Immunother"},{"issue":"1","key":"10.1016\/j.cellimm.2026.105100_bb0065","doi-asserted-by":"crossref","DOI":"10.1186\/s12896-025-01024-x","article-title":"A novel feeder cell based on 4-1BBL and membrane-bound IL-21\/IL-15 induce highly expansion and anti-tumor effect of natural killer cells","volume":"25","author":"Gong","year":"2025","journal-title":"BMC. Biotechnol"},{"issue":"4","key":"10.1016\/j.cellimm.2026.105100_bb0070","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1097\/00000658-198910000-00008","article-title":"Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients","volume":"210","author":"Rosenberg","year":"1989","journal-title":"Ann. Surg"},{"issue":"19","key":"10.1016\/j.cellimm.2026.105100_bb0075","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1158\/1078-0432.CCR-11-1347","article-title":"Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression","volume":"17","author":"Parkhurst","year":"2011","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.cellimm.2026.105100_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines13040857","article-title":"The role of NK cells in cancer immunotherapy: mechanisms, evasion strategies, and therapeutic advances","volume":"13","author":"Morcillo-Martin-Romo","year":"2025","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.cellimm.2026.105100_bb0085","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","article-title":"The emerging field of oncolytic virus-based cancer immunotherapy","volume":"9","author":"Ma","year":"2023","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.cellimm.2026.105100_bb0090","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.trecan.2023.09.012","article-title":"Integrating innate and adaptive immunity in oncolytic virus therapy","volume":"10","author":"DePeaux","year":"2024","journal-title":"Trends Cancer"},{"issue":"12","key":"10.1016\/j.cellimm.2026.105100_bb0095","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/s41417-023-00674-3","article-title":"Boosting cytotoxicity of adoptive allogeneic NK cell therapy with an oncolytic adenovirus encoding a human vIL-2 cytokine for the treatment of human ovarian cancer","volume":"30","author":"Quixabeira","year":"2023","journal-title":"Cancer. Gene. Ther"},{"issue":"526","key":"10.1016\/j.cellimm.2026.105100_bb0100","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax7992","article-title":"Intratumoral expression of IL-7 and IL-12 using an oncolytic virus increases systemic sensitivity to immune checkpoint blockade","volume":"12","author":"Nakao","year":"2020","journal-title":"Sci. Transl. Med"},{"issue":"12","key":"10.1016\/j.cellimm.2026.105100_bb0105","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1016\/j.ymthe.2022.06.010","article-title":"An armed oncolytic virus enhances the efficacy of tumor-infiltrating lymphocyte therapy by converting tumors to artificial antigen-presenting cells in situ","volume":"30","author":"Ye","year":"2022","journal-title":"Mol. Ther"},{"key":"10.1016\/j.cellimm.2026.105100_bb0110","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.biomaterials.2016.02.025","article-title":"Delivery of oncolytic adenovirus into the nucleus of tumorigenic cells by tumor microparticles for virotherapy","volume":"89","author":"Ran","year":"2016","journal-title":"Biomaterials"},{"issue":"15","key":"10.1016\/j.cellimm.2026.105100_bb0115","doi-asserted-by":"crossref","first-page":"16295","DOI":"10.1002\/cam4.6242","article-title":"YAP\/STAT3 inhibited CD8+ T cells activity in the breast cancer immune microenvironment by inducing M2 polarization of tumor-associated macrophages","volume":"12","author":"Wang","year":"2023","journal-title":"Cancer. Med"},{"key":"10.1016\/j.cellimm.2026.105100_bb0120","article-title":"Legumain protease-activated TAT-liposome cargo for targeting tumours and their microenvironment","volume":"5","author":"Liu","year":"2014","journal-title":"Nat. Commun"},{"issue":"1","key":"10.1016\/j.cellimm.2026.105100_bb0125","doi-asserted-by":"crossref","DOI":"10.1007\/s00018-024-05412-y","article-title":"Artificial antigen-presenting cells: the booster for the obtaining of functional adoptive cells","volume":"81","author":"Li","year":"2024","journal-title":"Cell. Mol. Life Sci"},{"issue":"7","key":"10.1016\/j.cellimm.2026.105100_bb0130","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.1016\/S2352-3026(25)00142-5","article-title":"Off-the-shelf induced pluripotent stem-cell-derived natural killer-cell therapy in relapsed or refractory b-cell lymphoma: a multicentre, open-label, phase 1 study","volume":"12","author":"Strati","year":"2025","journal-title":"Lancet. Haematol"},{"issue":"8","key":"10.1016\/j.cellimm.2026.105100_bb0135","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1016\/j.ccell.2024.07.007","article-title":"Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD","volume":"42","author":"Shanley","year":"2024","journal-title":"Cancer. Cell"},{"issue":"4","key":"10.1016\/j.cellimm.2026.105100_bb0140","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/JLB.4MR0620-091R","article-title":"Unraveling exhaustion in adaptive and conventional NK cells","volume":"108","author":"Merino","year":"2020","journal-title":"J. Leukoc. Biol"},{"issue":"19","key":"10.1016\/j.cellimm.2026.105100_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/cells11193147","article-title":"Next generation Immuno-oncology strategies: unleashing NK cells activity","volume":"11","author":"Mendoza-Valderrey","year":"2022","journal-title":"Cells"},{"issue":"22","key":"10.1016\/j.cellimm.2026.105100_bb0150","doi-asserted-by":"crossref","DOI":"10.3390\/cells13221924","article-title":"Emerging role of extracellular pH in tumor microenvironment as a therapeutic target for cancer immunotherapy","volume":"13","author":"Rahman","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.cellimm.2026.105100_bb0155","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1563303","article-title":"Impact of lactate on immune cell function in the tumor microenvironment: mechanisms and therapeutic perspectives","volume":"16","author":"Gu","year":"2025","journal-title":"Front. Immunol"},{"issue":"7","key":"10.1016\/j.cellimm.2026.105100_bb0160","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s41590-025-02178-8","article-title":"Targeting lactylation reinforces NK cell cytotoxicity within the tumor microenvironment","volume":"26","author":"Jin","year":"2025","journal-title":"Nat. Immunol"},{"issue":"7","key":"10.1016\/j.cellimm.2026.105100_bb0165","doi-asserted-by":"crossref","first-page":"721","DOI":"10.3390\/vaccines12070721","article-title":"The role of natural killer cells in oncolytic virotherapy: friends or foes?","volume":"12","author":"M.L","year":"2024","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.cellimm.2026.105100_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.950079","article-title":"Dendritic cells and natural killer cells: the road to a successful oncolytic virotherapy","volume":"13","author":"Ghasemi","year":"2023","journal-title":"Front. Immunol"},{"issue":"1","key":"10.1016\/j.cellimm.2026.105100_bb0175","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41417-024-00853-w","article-title":"Oncolytic virus encoding 4-1BBL and IL15 enhances the efficacy of tumor-infiltrating lymphocyte adoptive therapy in HCC","volume":"32","author":"Ye","year":"2025","journal-title":"Cancer. Gene. Ther"},{"issue":"1","key":"10.1016\/j.cellimm.2026.105100_bb0180","article-title":"Targeting metabolic-epigenetic-immune axis in cancer: molecular mechanisms and therapeutic implications","volume":"11","author":"Wang","year":"2026","journal-title":"Signal Transduct. Target. Ther"},{"issue":"10","key":"10.1016\/j.cellimm.2026.105100_bb0185","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.immuni.2023.09.005","article-title":"CD8+ t cells in the cancer-immunity cycle","volume":"56","author":"Giles","year":"2023","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.cellimm.2026.105100_bb0190","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8+ t cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat. Rev. Immunol"},{"key":"10.1016\/j.cellimm.2026.105100_bb0195","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1530541","article-title":"Adoptive cell therapy against tumor immune evasion: mechanisms, innovations, and future directions","volume":"15","author":"Ruan","year":"2025","journal-title":"Front. Oncol"},{"issue":"8","key":"10.1016\/j.cellimm.2026.105100_bb0200","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/s41590-020-0728-z","article-title":"The NK cell-cancer cycle: advances and new challenges in NK cell-based immunotherapies","volume":"21","author":"Bald","year":"2020","journal-title":"Nat. Immunol"},{"issue":"19","key":"10.1016\/j.cellimm.2026.105100_bb0205","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.cell.2023.07.034","article-title":"A pan-cancer single-cell panorama of human natural killer cells","volume":"186","author":"Tang","year":"2023","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.cellimm.2026.105100_bb0210","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/s41590-024-01884-z","article-title":"Pan-cancer profiling of tumor-infiltrating natural killer cells through transcriptional reference mapping","volume":"25","author":"Netskar","year":"2024","journal-title":"Nat. Immunol"},{"key":"10.1016\/j.cellimm.2026.105100_bb0215","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.681615","article-title":"Circulating and tumor-infiltrating NK cells from clear cell renal cell carcinoma patients exhibit a predominantly inhibitory phenotype characterized by overexpression of CD85j, CD45, CD48 and PD-1","volume":"12","author":"Ziblat","year":"2021","journal-title":"Front. Immunol"},{"issue":"8","key":"10.1016\/j.cellimm.2026.105100_bb0220","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1182\/blood-2009-11-253286","article-title":"CD62L expression identifies a unique subset of polyfunctional CD56dim NK cells","volume":"116","author":"Juelke","year":"2010","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.cellimm.2026.105100_bb0225","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.4049\/jimmunol.172.7.3994","article-title":"Cutting edge: CD96 (tactile) promotes NK cell-target cell adhesion by interacting with the poliovirus receptor (CD155)","volume":"172","author":"Fuchs","year":"2004","journal-title":"J. Immunol"},{"issue":"1","key":"10.1016\/j.cellimm.2026.105100_bb0230","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1006\/cimm.1994.1208","article-title":"CD54\/ICAM-1 is a costimulator of NK cell-mediated cytotoxicity","volume":"157","author":"Chong","year":"1994","journal-title":"Cell. Immunol"},{"issue":"8","key":"10.1016\/j.cellimm.2026.105100_bb0235","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.2022016200","article-title":"Allogeneic natural killer cell therapy","volume":"141","author":"Berrien-Elliott","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2026.105100_bb0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108103","article-title":"Oncolytic immunoViroTherapy: a long history of crosstalk between viruses and immune system for cancer treatment","volume":"236","author":"Feola","year":"2022","journal-title":"Pharmacol. Ther"},{"issue":"14","key":"10.1016\/j.cellimm.2026.105100_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17142296","article-title":"Cell carriers for oncolytic virus delivery: prospects for systemic administration","volume":"7","author":"Sarkisova","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"96","key":"10.1016\/j.cellimm.2026.105100_bb0250","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.adk4893","article-title":"Cytokines drive the formation of memory-like NK cell subsets via epigenetic rewiring and transcriptional regulation","volume":"9","author":"Foltz","year":"2024","journal-title":"Sci. Immunol"}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874926000407?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874926000407?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T20:17:47Z","timestamp":1777753067000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874926000407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":50,"alternative-id":["S0008874926000407"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2026.105100","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Armed oncolytic adenovirus elicits a \u201cself-feeder\u201d effect to supercharge NK cells for solid tumor control","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2026.105100","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"105100"}}